Last week, Insurer Cigna and pharmacy benefit manager (PBM) Express Scripts overcame 2 hurdles to completing their $67 billion merger as New York and California insurance regulators signed off on the deal.
Last week, Insurer Cigna and pharmacy benefit manager (PBM) Express Scripts overcame 2 hurdles to completing their $67 billion merger as New York and California insurance regulators signed off on the deal.
The deal, which was approved by the US Justice Department in September 2018, was approved by the insurance regulators with conditions. One of the conditions stipulated by the California Department of Managed Health Care was that the combined company not raise premiums to pay for the merger for 5 years and keep premium prices “to a minimum.”
Additionally, Cigna and Express Scripts have agreed to invest $60 million in California’s healthcare system through Cigna’s accountable care organizations as well as funding scholarships and loan repayment programs to increase the number of healthcare providers in underserved areas. These funds will also go towards supporting programs that address social determinants of health and the opioid epidemic.
Another condition, required by New York regulators, was that the combined company wouldn’t increase premiums for New York plan members to pay for the acquisition, as well as providing preferential pricing from Express Scripts or excluding independent pharmacies from its network.
Such factors are a concern because they would give Cigna an “artificial competitive advantage that would draw policyholders away from other insurers and create an even larger market share for the enterprise,” according to the December 13, 2018 filing. Finally, the regulator also required the insurer to report the pharmacy rebates it receives, and the amount returned to customers.
New York’s financial services department had a public hearing scheduled to discuss the merger on January 10, 2019, but later decided it wasn’t necessary after Cigna agreed to the terms presented.
As of now, the final state that has yet to grant approval of the merger is New Jersey. “We continue to work with regulators in New Jersey, the [1] outstanding state where approval is required, and continue to expect that the transaction will close by the end of 2018, subject to the satisfaction of all closing conditions,” read the filing.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.